Other Highlights - Hepatitis - Clinical Care Options

Highlights From AASLD 2013: Other Highlights and Special Populations

In this CME-certified slideset, Jordan J. Feld, MD, MPH; Paul Y. Kwo, MD; and Nancy Reau, MD, review the most clinically relevant data on special populations from the 2013 American Association for the Study of Liver Diseases annual meeting.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Faculty: Jordan J. Feld MD, MPH, Paul Y. Kwo MD, Nancy Reau MD

Released: 1/23/2014
Other Highlights & Special Populations

Paul Y. Kwo, MD; Jordan J. Feld, MD, MPH; and Nancy Reau, MD, highlight the most clinically relevant data on HCV screening and natural history, management of special HCV-infected populations, and hepatitis B from the AASLD meeting.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/20/2013
Fibrosis Stage, but Not NAS, Is Associated With Increased Overall and Disease-Specific Mortality in a Cohort of Patients With NAFLD With 26 Years of Follow-up

In this large cohort of patients from 2 earlier studies with long-term follow-up, fibrosis stage was found to be more accurate than NAS for predicting overall and disease-specific mortality.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/8/2013
Birth Cohort Screening in an Emergency Department Setting Is Effective at Identifying Unrecognized Chronic HCV Infection Among Individuals Belonging to 1945-1965 Birth Cohort

In this pilot study, preliminary data reveal disproportionately high HCV prevalence rates among males and the uninsured/underinsured.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/8/2013
Interim Data Indicate HBV Reactivation Rates Increased for Patients Anti-HBsAg Antibody Negative, Anti-HBcAg Positive at Baseline

The HBV reactivation rate for patients anti-HBsAg negative, anti-HBcAg positive is 24.2% when they are treated with rituximab-based chemotherapy for hematologic malignancies.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/7/2013
Pretransplantation Sofosbuvir Plus RBV Prevents HCV Recurrence in Individuals Who Have Received Liver Transplantation, With Good Tolerability

Patients who achieved > 30 consecutive days with HCV RNA target not detected before transplantation were highly likely to remain free of HCV recurrence 12 weeks after transplantation.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/7/2013
Meta-analysis of Individual Patient Data From 10 Studies Indicates That Patients With HCV-Associated Cirrhosis Remain at Risk for Developing HCC After Achieving SVR

Meta-analysis of data from 10 patient cohort studies found that the ongoing risk of developing HCC for patients with HCV-induced cirrhosis and who achieve SVR is approximately 1% with the risk increasing with advanced age, more severe liver disease, or diabetes.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/6/2013
PHOTON-1: Phase III Efficacy and Safety of Sofosbuvir Plus RBV in HCV Treatment-Naive Patients Coinfected With HIV and HCV Genotype 1, 2, or 3

In a phase III trial, 76% of patients with genotype 1 HCV achieved SVR12 with 24 weeks of therapy; 88% of patients with genotype 2 HCV and 67% with genotype 3 HCV achieved SVR12 with 12 weeks of therapy.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/6/2013
Efficacy of PegIFN/RBV Plus Boceprevir or Telaprevir for Genotype 1 HCV Recurrence Following Liver Transplantation Tempered by Adverse Events

Patients experiencing recurrence of genotype 1 HCV infections following liver transplantation achieved SVR12 with boceprevir plus pegIFN/RBV of 51% and 41% achieved SVR12 with telaprevir plus pegIFN/RBV, but ≥ 50% discontinued therapy due to adverse events or virologic failure.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/6/2013
INSIGHT: Interim Efficacy and Safety Data From Phase III Trial of Telaprevir Plus PegIFN/RBV in HCV/HIV-Coinfected Patients

A total of 72% of HCV/HIV-coinfected patients achieved undetectable HCV RNA after 12 weeks of treatment with telaprevir plus pegIFN/RBV and 99% maintained HIV-1 RNA < 50 copies/mL while on therapy.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases

Date Posted: 11/5/2013

Other Sites

Topics

Educational Formats

Program Resources

User Resources

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Other Highlights Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases*
Conference Program Investigational HCV • Capsule Summaries (14) • CCO Slideset (CME) • Downloadable slideset Other Highlights • Capsule Summaries (11) • CCO Slideset (CME) • Downloadable slideset	Latest Content 10 of 13 Shown Highlights From AASLD 2013: Other Highlights and Special Populations In this CME-certified slideset, Jordan J. Feld, MD, MPH; Paul Y. Kwo, MD; and Nancy Reau, MD, review the most clinically relevant data on special populations from the 2013 American Association for the Study of Liver Diseases annual meeting. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Faculty: Jordan J. Feld MD, MPH, Paul Y. Kwo MD, Nancy Reau MD Released: 1/23/2014 Other Highlights & Special Populations Paul Y. Kwo, MD; Jordan J. Feld, MD, MPH; and Nancy Reau, MD, highlight the most clinically relevant data on HCV screening and natural history, management of special HCV-infected populations, and hepatitis B from the AASLD meeting. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/20/2013 Fibrosis Stage, but Not NAS, Is Associated With Increased Overall and Disease-Specific Mortality in a Cohort of Patients With NAFLD With 26 Years of Follow-up In this large cohort of patients from 2 earlier studies with long-term follow-up, fibrosis stage was found to be more accurate than NAS for predicting overall and disease-specific mortality. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/8/2013 Birth Cohort Screening in an Emergency Department Setting Is Effective at Identifying Unrecognized Chronic HCV Infection Among Individuals Belonging to 1945-1965 Birth Cohort In this pilot study, preliminary data reveal disproportionately high HCV prevalence rates among males and the uninsured/underinsured. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/8/2013 Interim Data Indicate HBV Reactivation Rates Increased for Patients Anti-HBsAg Antibody Negative, Anti-HBcAg Positive at Baseline The HBV reactivation rate for patients anti-HBsAg negative, anti-HBcAg positive is 24.2% when they are treated with rituximab-based chemotherapy for hematologic malignancies. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/7/2013 Pretransplantation Sofosbuvir Plus RBV Prevents HCV Recurrence in Individuals Who Have Received Liver Transplantation, With Good Tolerability Patients who achieved > 30 consecutive days with HCV RNA target not detected before transplantation were highly likely to remain free of HCV recurrence 12 weeks after transplantation. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/7/2013 Meta-analysis of Individual Patient Data From 10 Studies Indicates That Patients With HCV-Associated Cirrhosis Remain at Risk for Developing HCC After Achieving SVR Meta-analysis of data from 10 patient cohort studies found that the ongoing risk of developing HCC for patients with HCV-induced cirrhosis and who achieve SVR is approximately 1% with the risk increasing with advanced age, more severe liver disease, or diabetes. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/6/2013 PHOTON-1: Phase III Efficacy and Safety of Sofosbuvir Plus RBV in HCV Treatment-Naive Patients Coinfected With HIV and HCV Genotype 1, 2, or 3 In a phase III trial, 76% of patients with genotype 1 HCV achieved SVR12 with 24 weeks of therapy; 88% of patients with genotype 2 HCV and 67% with genotype 3 HCV achieved SVR12 with 12 weeks of therapy. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/6/2013 Efficacy of PegIFN/RBV Plus Boceprevir or Telaprevir for Genotype 1 HCV Recurrence Following Liver Transplantation Tempered by Adverse Events Patients experiencing recurrence of genotype 1 HCV infections following liver transplantation achieved SVR12 with boceprevir plus pegIFN/RBV of 51% and 41% achieved SVR12 with telaprevir plus pegIFN/RBV, but ≥ 50% discontinued therapy due to adverse events or virologic failure. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/6/2013 INSIGHT: Interim Efficacy and Safety Data From Phase III Trial of Telaprevir Plus PegIFN/RBV in HCV/HIV-Coinfected Patients A total of 72% of HCV/HIV-coinfected patients achieved undetectable HCV RNA after 12 weeks of treatment with telaprevir plus pegIFN/RBV and 99% maintained HIV-1 RNA < 50 copies/mL while on therapy. Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases Date Posted: 11/5/2013 10 of 13 Shown Show 3 More Loading...	Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC Contact Info In partnership with Educational grants provided by: Educational grants support only the CME-certified components of this program.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Source: 2013 Annual Meeting of the American Association for the Study of Liver Diseases*

Conference Program

Latest Content